An 8‐year follow‐up of anti‐vascular endothelial growth factor treatment with a treat‐and‐extend modality for neovascular age‐related macular degeneration
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Purpose: To investigate long‐term visual results of treatment with anti‐vascular endothelial growth factor (VEGF) agents for neovascular age‐related macular degeneration (nAMD) following a treat‐and‐extend regimen. Methods: Retrospective review of 155 patients who initiated treatment with bevacizumab for nAMD in one eye. At the final 8‐year visit, 40 patients (26%) remained for follow‐up. Mean change in best‐corrected visual acuity (BCVA) was calculated compared to baseline values. Results: Mean BCVA improved significantly from baseline during the first year of treatment, with −0.11 log MAR units equivalent to 6.1 approximate Early Treatment Diabetic Retinopathy Study (approx ETDRS) letters (p = <0.001). Mean BCVA was still significantly improved after 4 years of treatment for the entire group of patients and after 6 years of treatment for the subgroup of 40 patients who remained at the final 8‐year visit. Thereafter, BCVA gradually declined and at 8 years, there was a mean change of 0.05 log MAR units equivalent to 2.1 approx ETDRS letters below baseline (p = 0.530). Mean number of injections during the first year was 6.1 ± 2.8 and during year 8 was 5.4 ± 3.5. At 5 years, fundus autofluorescence showed some degree of macular atrophy in all eyes. At the final 8‐year visit, 87.5% of the eyes had stable neovascular lesions with no fluid on optical coherence tomography (OCT). Conclusion: In an everyday clinical setting, treatment of nAMD patients with a treat‐and‐extend modality provided improvement and stability of vision for several years. After 8 years of follow‐up, there was a decline in visual acuity (VA) that could be explained by macular atrophic development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886 · cited 2×
“Pivotal randomized clinical trials demonstrated excellent visual gain after 2 years of monthly treatment with ranibizumab (Rosenfeld et al. 2006; Brown et al. 2009).”
BackgroundInfluentialRanibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Rofagha, S., Bhisitkul, R. B., Boyer, D. S., Sadda, S. R., & Zhang, K. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.046 · Cited by 1,023 · cited 3×
“The SEVENUP study assessed 7- to 8-year outcomes in patients who had been treated in the MARINA and ANCHOR studies (Rofagha et al. 2013).”
BackgroundMethodInfluentialMaguire, M. G., Martin, D. F., Ying, G.-S., Jaffe, G. J., Daniel, E., Grunwald, J. E., Toth, C. A., Ferris, F. L., & Fine, S. L. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.045 · Cited by 708 · cited 1×
“One endophthalmitis following bevacizumab, one endophthalmitis following cataract surgery, one pseudoendophthalmitis following ranibizumab, one central retinal arterial occlusion, one herpes keratitis. a decrease in mean BCVA with 3 ETDRS letters below baseline (Maguire et al. 2016).”
BackgroundRisk of geographic atrophy in the comparison of age-related macular degeneration treatments trials
Grunwald, J. E., Daniel, E., Huang, J., Ying, G.-S., Maguire, M. G., Toth, C. A., Jaffe, G. J., Fine, S. L., Blodi, B., Klein, M. L., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.015 · Cited by 590
Incidence of Legal Blindness From Age-Related Macular Degeneration in Denmark: Year 2000 to 2010
Bloch, S. B., Larsen, M., & Munch, I. C. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.10.016 · Cited by 377
Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials
Daniel, E., Toth, C. A., Grunwald, J. E., Jaffe, G. J., Martin, D. F., Fine, S. L., Huang, J., Ying, G.-S., Hagstrom, S. A., Winter, K., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.019 · Cited by 335 · cited 1×
“While RAP lesions were less likely to develop scarring, classic lesions were a predictor for scarring at 2 years in the CATT subanalysis (Daniel et al. 2014, 2016).”
BackgroundMunk, M. R., Ceklic, L., Ebneter, A., Huf, W., Wolf, S., & Zinkernagel, M. S. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13157 · Cited by 107
Cited by
Evans, R. N., Reeves, B. C., Phillips, D., Muldrew, K. A., Rogers, C., Harding, S. P., & Chakravarthy, U. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.03.020 · Cited by 28
Starr, M. R., Kung, F. F., Mejia, C. A., Bui, Y. T., & Bakri, S. J. (2020) · Retina · doi:10.1097/iae.0000000000002668 · Cited by 22
Hertzberg, S. N. W., Jørstad, Ø. K., Petrovski, B. É., Bragadottir, R., Steffensen, L. A., Moe, M. C., Burger, E. A., & Petrovski, G. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191912603 · Cited by 6
Metadata
- Authors
- Berg, K., Roald, A. B., Navaratnam, J., & Bragadóttir, R.
- Venue
- Acta Ophthalmologica
- Publisher
- Wiley
- Published
- 2017-09-19
- Volume
- 95
- Issue
- 8
- Pages
- 796-802
- ISSN
- 0001-639X (ISSN-L)
- 1755-375X
- 1755-3768
- OpenAlex
- W2754502683
- Cited by
- 69
- References
- 9
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An 8‐year follow‐up of anti‐vascular endothelial growth factor treatment with a treat‐and‐extend modality for neovascular age‐related macular degeneration. https://app.cochat.ai/papers/10.1111/aos.13522
- The paper
- Berg, K., Roald, A. B., Navaratnam, J., & Bragadóttir, R. (2017). An 8‐year follow‐up of anti‐vascular endothelial growth factor treatment with a treat‐and‐extend modality for neovascular age‐related macular degeneration. Acta Ophthalmologica. https://doi.org/10.1111/aos.13522
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.